Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

An epigenetic editing therapy, MDL-101 includes a guide nucleotide targeting the LAMA1 gene — a close homolog of the ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Conformational changes on the capsid may be the cause of the charge differences between empty and full AAV capsids.

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

In this GEN webinar, experts from Regeneron Pharmaceuticals will discuss two novel methods for characterizing AAV-based gene ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Dyno has formed a new research partnership with Roche on the development of AAV gene therapy vectors for neurological ...

MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...